1. A method for for the protection from oxidation andor electromagnetic radiation of a compound sensitive to oxidation andor to electromagnetic radiation, the method comprising contacting said compound with at least one metal organosilicate polymer compound, in the form of particles, having one of the following formulae I and II:
R4Si4Al2O8(OH)x, \u2003\u2003Formula I:
R8Si8M6O16(OH)y, \u2003\u2003Formula II:
in which:
each R is chosen, independently of the others, from the group formed by a substituted or unsubstituted and linear or branched alkyl group, a substituted or unsubstituted and linear or branched alkenyl group, a substituted or unsubstituted aryl group and a substituted or unsubstituted benzyl group,
x\u22672,
y\u22674,
in the formula I, the SiAl ratio is between 1.8 and 1.3 inclusive,
in the formula II, M is chosen from the group formed by calcium, magnesium, zinc, strontium and the mixtures of these, and the SiM molar ratio is between 1.8 and 1.3 inclusive.
2. The method as claimed in claim 1, wherein each R is chosen, independently of the others, from a substituted or unsubstituted methyl group, a substituted or unsubstituted ethyl group, a substituted or unsubstituted n-propyl group and a substituted or unsubstituted benzyl group.
3. The method as claimed in claim 1, wherein, when R is substituted, it is substituted by at least one amino group, one halogen atom, one ether group, one ester group, one hydroxyl group, one acrylate group, one epoxy group, one alkyl group, one alkyl acrylate group, one aminoalkyl group or one chloroalkyl group.
4. The method as claimed in claim 1, wherein the metal organosilicate polymer has the formula II in which M is zinc or magnesium and each R is a 3-aminopropyl group.
5. The method as claimed in claim 1, wherein the metal organosilicate polymer has the formula II in which M is zinc or magnesium and each R is an N-(2-aminoethyl)-3-propylamine group.
6. The method as claimed in claim 1, wherein the compound sensitive to oxidation andor to electromagnetic radiation is an organic fluorophoric compound.
7. The method as claimed in claim 6, wherein the organic fluorophoric compound is chosen from the group formed by rhodamine, fluorescein, porphyrins and their mixtures.
8. The method as claimed in claim 1, wherein the compound sensitive to oxidation andor to electromagnetic radiation is a benzotriazole compound.
9. The method as claimed in claim 8, wherein the benzotriazole compound is 2-(2\u2032-hydroxy-5\u2032-methylphenyl)benzotriazole and wherein the metal organosilicate polymer has the formula II in which M is zinc (Zn) and four R groups are NH2(CH2)3 groups and four R groups are C6H5 groups.
10. A fluorescent composition, which comprises:
particles of at least one organic fluorophoric compound, and
particles of at least one metal organosilicate polymer having one of the following formulae I and II:
R4Si4Al2O8(OH)x, \u2003\u2003Formula I:
R8Si8M6O1(OH)y, \u2003\u2003Formula II:
in which:
each R is chosen, independently of the others, from the group formed by a substituted or unsubstituted and linear or branched alkyl group, a substituted or unsubstituted and linear or branched alkenyl group, a substituted or unsubstituted aryl group and a substituted or unsubstituted benzyl group,
x\u22672,
y\u22674,
in the formula I, the SiAl ratio is between 1.8 and 1.3 inclusive,
in the formula II, M is chosen from the group formed by calcium, magnesium, zinc, strontium and the mixtures of these, and the SiM molar ratio is between 1.8 and 1.3 inclusive.
11. The fluorescent composition as claimed in claim 10, wherein the organic fluorophoric compound is chosen from the group formed by rhodamine, fluorescein, porphyrins and their mixtures.
12. The composition as claimed in claim 10, wherein, in the formulae I and II, each R is chosen, independently of the others, from a substituted or unsubstituted methyl group, a substituted or unsubstituted ethyl group, a substituted or unsubstituted n-propyl group and a substituted or unsubstituted benzyl group.
13. The fluorescent composition as claimed in claim 10, wherein, in the formulae I and II, when R is substituted, it is substituted by at least one amino group, one halogen atom, one ether group, one ester group, one hydroxyl group, one acrylate group, one epoxy group, one alkyl group, one alkyl acrylate group, one aminoalkyl group or one chloroalkyl group.
14. The fluorescent composition as claimed in claim 10, wherein the metal organosilicate polymer has the formula II in which M is magnesium or zinc and each R is an aminopropyl group.
15. The fluorescent composition as claimed in claim 10, wherein the metal organosilicate polymer has the formula II in which M is magnesium or zinc and each R is an N-(2-aminoethyl)-3-propylamine group.
16. The fluorescent composition as claimed in claim 10, which is in the form of solid particles.
17. The fluorescent composition as claimed in claim 10, which is in the form of a dispersion or of a colloidal sol, preferably in an aqueous phase.
18. A marking composition, which comprises at least one composition as claimed in claim 10.
19. A composition for protecting from UV radiation, which comprises:
2-(2\u2032-hydroxy-5\u2032-methylphenyl)benzotriazole and
particles of at least one metal organosilicate polymer having one of the following formulae I and II:
R4Si4Al2O8(OH)x, \u2003\u2003Formula I:
R8Si8M6O16(OH)y, \u2003\u2003Formula II:
in which:
each R is chosen, independently of the others, from the group formed by a substituted or unsubstituted and linear or branched alkyl group, a substituted or unsubstituted and linear or branched alkenyl group, a substituted or unsubstituted aryl group and a substituted or unsubstituted benzyl group,
x\u22672,
y\u22674,
in the formula I, the SiAl ratio is between 1.8 and 1.3 inclusive,
in the formula II, M is chosen from the group formed by calcium, magnesium, zinc, strontium and the mixtures of these, and the SiM molar ratio is between 1.8 and 1.3 inclusive.
20. The composition as claimed in claim 19, wherein each R is chosen, independently of the others, from a substituted or unsubstituted methyl group, a substituted or unsubstituted ethyl group, a substituted or unsubstituted n-propyl group and a substituted or unsubstituted benzyl group.
21. The composition as claimed in claim 19, wherein, in the formulae I and II, when R is substituted, it is substituted by at least one amino group, one halogen atom, one ether group, one ester group, one hydroxyl group, one acrylate group, one epoxy group, one alkyl group, one alkyl acrylate group, one aminoalkyl group or one chloroalkyl group.
22. The composition as claimed in claim 19, wherein the metal organosilicate polymer has the formula II in which M is zinc (Zn) and four R groups are NH2(CH2)2NH(CH2)3 groups and four R groups are C6H5 groups.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A compound of the formula:
an enantiomer or a prodrug thereof, or a pharmaceutically acceptable salt of any of the foregoing.
2. A compound of the formula:
an enantiomer or a prodrug thereof, or a pharmaceutically acceptable salt of any of the foregoing.
3. A compound of the formula:
an enantiomer or a prodrug thereof, or a pharmaceutically acceptable salt of any of the foregoing.
4. A compound of the formula:
an enantiomer or a prodrug thereof, or a pharmaceutically acceptable salt of any of the foregoing.
5. A composition comprising:
(a) an amount of the compound as claimed in claim 1, an enantiomer thereof, a prodrug thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a combination of two or more of the foregoing, and
(b) at least one auxiliary substance.
6. A composition comprising:
(a) an amount of the compound as claimed in claim 2, an enantiomer thereof, a prodrug thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a combination of two or more of the foregoing, and
(b) at least one auxiliary substance.
7. A composition comprising:
(a) an amount of the compound as claimed in claim 3, an enantiomer thereof, a prodrug thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a combination of two or more of the foregoing, and
(b) at least one auxiliary substance.
8. A composition comprising:
(a) an amount of the compound as claimed in claim 4, an enantiomer thereof, a prodrug thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a combination of two or more of the foregoing, and
(b) at least one auxiliary substance.
9. The composition of one of claims 5, 6, 7, and 8, wherein the amount is an amount effective for treating at least one disorder involving cannabinoid neurotransmission wherein the cannabinoid neurotransmission disorder is selected from the group consisting of psychosis, anxiety, depression, attention deficits, memory disorders, cognitive disorders, appetite disorders, obesity, addition, appetence, drug dependence, dementia, dystonia, muscle spasticity, tremor, epilepsy, multiple sclerosis, traumatic brain injury, stroke, Parkinson’s disease, Alzheimer’s disease, epilepsy, Huntington’s disease, Tourette’s Syndrome, cerebral ischaemia, cerebral apoplexy, craniocerebral trauma, spinal cord injury, plaque sclerosis, viral encephalitis, pain, septic shock, glaucoma, diabetes, emesis, nausea, asthma, gastric ulcers, and diarrhea.
10. A method of treating at least one disorder involving cannabinoid neurotransmission wherein the cannabinoid neurotransmission disorder is selected from the group consisting of psychosis, anxiety, depression, attention deficits, memory disorders, cognitive disorders, appetite disorders, obesity, addiction, appetence, drug dependence, dementia, dystonia, muscle spasticity, tremor, epilepsy, multiple sclerosis, traumatic brain injury, stroke, Parkinson’s disease, Alzheimer’s disease, epilepsy, Huntington’s disease, Tourette’s Syndrome, cerebral ischaemia, cerebral apoplexy, craniocerebral trauma, spinal cord injury, plaque sclerosis, viral encephalitis, pain, septic shock, glaucoma, diabetes, emesis, nausea, asthma, gastric ulcers, and diarrhea in a human or animal patient in need of such treating, comprising administering to the patient an amount effective for the treating of a compound as claimed in claim 1, an enantiomer thereof, a prodrug thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a combination of two or more of the foregoing.
11. A method of treating at least one disorder involving cannabinoid neurotransmission wherein the cannabinoid neurotransmission disorder is selected from the group consisting of psychosis, anxiety, depression, attention deficits, memory disorders, cognitive disorders, appetite disorders, obesity, addition, appetence, drug dependence, dementia, dystonia, muscle spasticity, tremor, epilepsy, multiple sclerosis, traumatic brain injury, stroke, Parkinson’s disease, Alzheimer’s disease, epilepsy, Huntington’s disease, Tourette’s Syndrome, cerebral ischaemia, cerebral apoplexy, craniocerebral trauma, spinal cord injury, plaque sclerosis, viral encephalitis, pain, septic shock, glaucoma, diabetes, emesis, nausea, asthma, gastric ulcers, and diarrhea in a human or animal patient in need of such treating, comprising administering to the patient an amount effective for the treating of a compound as claimed in claim 2, an enantiomer thereof, a prodrug thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a combination of two or more of the foregoing.
12. A method of treating at least one disorder involving cannabinoid neurotransmission wherein the cannabinoid neurotransmission disorder is selected from the group consisting of psychosis, anxiety, depression, attention deficits, memory disorders, cognitive disorders, appetite disorders, obesity, addition, appetence, drug dependence, dementia, dystonia, muscle spasticity, tremor, epilepsy, multiple sclerosis, traumatic brain injury, stroke, Parkinson’s disease, Alzheimer’s disease, epilepsy, Huntington’s disease, Tourette’s Syndrome, cerebral ischaemia, cerebral apoplexy, craniocerebral trauma, spinal cord injury, plaque sclerosis, viral encephalitis, pain, septic shock, glaucoma, diabetes, emesis, nausea, asthma, gastric ulcers, and diarrhea in a human or animal patient in need of such treating, comprising administering to the patient an amount effective for the treating of a compound as claimed in claim 3, an enantiomer thereof, a prodrug thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a combination of two or more of the foregoing.
13. A method of treating at least one disorder involving cannabinoid neurotransmission wherein the cannabinoid neurotransmission disorder is selected from the group consisting of psychosis, anxiety, depression, attention deficits, memory disorders, cognitive disorders, appetite disorders, obesity, addition, appetence, drug dependence, dementia, dystonia, muscle spasticity, tremor, epilepsy, multiple sclerosis, traumatic brain injury, stroke, Parkinson’s disease, Alzheimer’s disease, epilepsy, Huntington’s disease, Tourette’s Syndrome, cerebral ischaemia, cerebral apoplexy, craniocerebral trauma, spinal cord injury, plaque sclerosis, viral encephalitis, pain, septic shock, glaucoma, diabetes, emesis, nausea, asthma, gastric ulcers, and diarrhea in a human or animal patient in need of such treating, comprising administering to the patient an amount effective for the treating of a compound as claimed in claim 4, an enantiomer thereof, a prodrug thereof, or a pharmaceutically acceptable salt of any of the foregoing, or a combination of two or more of the foregoing.